About
MNI Leadership Board
HCP Resources
Education
HCP Consensus Statements from
CJON
HCP Toolkits
ctDNA Testing for Response Monitoring
BRAF Testing
Care Step Pathways
Facebook Q&A Community
Videos
HCP Videos
Patient Videos
Decision Support Tools
Options for Stage II Melanoma
Options for Stage III Melanoma
Options for Stage IV Melanoma
Patient Resources
Patient Action Plans
Non-Invasive Evaluation Tools For Suspicious Spots
Side Effect Search
BRAF Q&A
ctDNA Testing Handout
Oncolytic Viruses
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
About
MNI Leadership Board
HCP Resources
Education
HCP Consensus Statements from
CJON
HCP Toolkits
ctDNA Testing for Response Monitoring
BRAF Testing
Care Step Pathways
Facebook Q&A Community
Videos
HCP Videos
Patient Videos
Decision Support Tools
Options for Stage II Melanoma
Options for Stage III Melanoma
Options for Stage IV Melanoma
Patient Resources
Patient Action Plans
Non-Invasive Evaluation Tools For Suspicious Spots
Side Effect Search
BRAF Q&A
ctDNA Testing Handout
Oncolytic Viruses
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Side Effect of Therapy
Institute drug-specific recommended dosage holds/discontinuations based on severity
Copyright ©2023- - The Melanoma Nursing Initiative. All rights reserved.
